Incidence and Predictors of Second Primary Cancers in Patients With Neuroendocrine Tumors

Sarah B Bateni; Natalie G Coburn; Calvin H L Law; Simron Singh; Sten Myrehaug; Angela Assal; Julie Hallet

doi:10.1001/jamaoncol.2021.4531

Incidence and Predictors of Second Primary Cancers in Patients With Neuroendocrine Tumors

JAMA Oncol. 2021 Nov 1;7(11):1718-1720. doi: 10.1001/jamaoncol.2021.4531.

Authors

Sarah B Bateni^{1

2}, Natalie G Coburn^{1

2}, Calvin H L Law^{1

2}, Simron Singh^{3

4}, Sten Myrehaug^{5

6}, Angela Assal^{4

7}, Julie Hallet^{1

2}

Affiliations

¹ Division of General Surgery, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
² Division of General Surgery, University of Toronto, Toronto, Ontario, Canada.
³ Division of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
⁴ Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
⁵ Division of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
⁶ Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.
⁷ Division of Endocrinology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.

Abstract

This retrospective cohort study examines the risk factors and predictors of second primary cancers after being diagnosed with neuroendocrine tumors.

MeSH terms

Humans
Incidence
Neoplasms, Second Primary* / etiology
Neuroendocrine Tumors* / epidemiology
Neuroendocrine Tumors* / pathology
Prognosis